Results 131 to 140 of about 8,134 (194)

Long-term Empagliflozin Use in Chronic Syndrome of Inappropriate Antidiuresis Due to Traumatic Subarachnoid Hemorrhage. [PDF]

JCEM Case Rep
Kyriakidou A, Shekhda KM, Waung JA, Tzoulis P.   +3 more
europepmc   +1 more source

Impact of visceral adipose tissue on eGFR slope in early ADPKD: evidence from a real-world cohort. [PDF]

Clin Kidney J
Capelli I, Sanfilippo I, Valeri L, Vetrano D, Lorenzini G, Sciascia N, Aiello V, Lerario S, Ciurli F, La Manna G, Corsi C.   +10 more
europepmc   +1 more source

Revisiting the Role of Tolvaptan in the Management of Hyponatraemia in Acute Heart Failure: Balancing Quality of Life and Cost With Tolvaptan Treatment. [PDF]

Cureus
Olaogun I, Young EE, Anyim OB.
europepmc   +1 more source

Case Report: One case of pregnancy complicated by large cell neuroendocrine carcinoma of the cervix with syndrome of inappropriate secretion of antidiuretic hormone. [PDF]

Front Oncol
Dong C, Zhu B, Miao G, Zheng Z.
europepmc   +1 more source

Beyond dyspnoea as an endpoint in acute heart failure trials [PDF]

, 2017
Gheorghiade, Mihai, Ruschitzka, Frank
core  

Long-Term Effects of Tolvaptan Therapy on Total Kidney Volume and Renal Function in Patients with Autosomal Dominant Polycystic Kidney Disease: A Single-Center Experience. [PDF]

J Clin Med
Filiopoulos V, Kofotolios I, Vallianou K, Karavasilis E, Ntounas G, Melexopoulou C, Marinaki S.   +6 more
europepmc   +1 more source

Safety and Efficacy of Tolvaptan for Acute Refractive Hyponatremia Associated with Traumatic Brain Injury. [PDF]

J Clin Med
Desai S, Holsaeter K, Winski A, Barletta JF, Bauer F.   +4 more
europepmc   +1 more source

Prognostic impact of the acute reactiveness to intravenous administration of tolvaptan sodium phosphate in patients with acute decompensated heart failure. [PDF]

Eur Heart J Open
Ouchi S, Iwata H, Moriya S, Naito R, Takahashi N, Kasai T, Minamino T.   +6 more
europepmc   +1 more source

Tolvaptan versus other interventions for hyponatraemia in people with cirrhosis. [PDF]

Cochrane Database Syst Rev
Anila KN, Saraswathy NS, Mohamed ZU, Varghese CT, Binoj ST, Gopalakrishnan U, Balakrishnan D, Valsan A, Sudhindran S.   +8 more
europepmc   +1 more source

Relcovaptan: a promising therapeutic agent in traumatic spinal cord injury that acts by modulating newly identified transcriptional regulators of aquaporins compared to tolvaptan. [PDF]

Turk J Med Sci
Iş Ş, Ceman D, Iş M, Keser N, Tekin Ş.   +4 more
europepmc   +1 more source